---
id: health-genomic-clinical-trials
title: Healthcare: Multi-Omics Oncology Platform & Clinical Trial Matching Engine
category: healthcare
language: null
functionName: solution
executable: false
---
Act as the Chief Medical Information Officer and Principal Bioinformatics Architect for a National Cancer Institute (NCI)-designated Comprehensive Cancer Center network (1.4 million patients, 60,000 active cancer patients, 450 concurrent oncology clinical trials). You are architecting an enterprise multi-omics clinical decision support and automated precision clinical trial matching platform.

Less than 5% of adult cancer patients enroll in clinical trials due to fragmented electronic health record (EHR) systems, unstructured pathology reports, complex multi-gene genomic variant nomenclature (VCF files from Next-Generation Sequencing), and constantly evolving trial eligibility criteria (e.g. specific co-mutations, prior therapy exclusions, biomarker expression cutoffs).

### Deliverables & Section Requirements:

#### 1. Multi-Modal Biomedical Data Integration Architecture
- Enterprise biomedical data lakehouse topology integrating:
  - Clinical Data: HL7 FHIR R4 resources (Patient, Condition, Observation, MedicationStatement, Procedure) mapped from Epic/Cerner EHRs into the OMOP Common Data Model (CDM).
  - Genomic & Multi-Omics Data: Ingestion of Variant Call Format (VCF) files, RNA-seq gene expression quantification, immunohistochemistry (IHC) protein biomarkers, and liquid biopsy ctDNA assays.
  - Unstructured Pathology & Imaging: Real-time NLP extraction from unstructured surgical pathology PDF reports and radiology RECIST criteria tumor measurements.
- HIPAA, HITECH, and HITRUST certified security architecture: De-identification pipelines under HIPAA Safe Harbor and Expert Determination, zero-trust access control, and audit trail logging.

#### 2. Clinical Trial Eligibility Representation & Knowledge Graph
- Algorithmic translation of unstructured clinical trial protocols into machine-executable Boolean and graph-based eligibility criteria:
  - Clinical trial knowledge graph schema: Protocol Nodes, Biomarker Criteria Nodes (inclusion/exclusion), Prior Line of Therapy Nodes, and Lab Value Thresholds.
- Biomarker classification hierarchy: mapping variant aliases from ClinVar, OncoKB, CIViC, and COSMIC (e.g. resolving BRAF V600E, EGFR exon 19 deletions, KRAS G12C, HER2/neu amplification, and Microsatellite Instability High / MSI-H).

#### 3. Patient-to-Trial Matching Algorithm & Scoring Engine
Provide a comprehensive matching demonstration table evaluating 5 representative, complex oncology patient profiles against active clinical trials:
- **Patient ID & Clinical Profile** (Stage, Histology, Performance Status ECOG, Prior Therapies).
- **Genomic Alterations & Biomarkers** (e.g. KRAS G12D, TP53 mut, PD-L1 TPS = 65%).
- **Matched Clinical Trial (NCT ID & Phase)**.
- **Match Tier** (Tier 1: Exact Biomarker + Line of Therapy Match; Tier 2: Basket/Umbrella Trial Molecular Match; Tier 3: Off-Label Novel Target).
- **Inclusion Criteria Satisfied & Exclusion Criteria Evaluated** (confirming no exclusionary autoimmune disease, organ dysfunction, or prior target inhibitor failure).
- **Match Confidence Score (0-100%) & Priority Ranking**.

#### 4. Molecular Tumor Board (MTB) Decision Support Interface
- Functional specification of the clinician-facing Molecular Tumor Board summary report:
  - Genomic landscape visualization (tumor mutational burden / TMB, microsatellite status, actionable tier 1-4 variants).
  - Evidence-based therapeutic recommendations graded by level of evidence (FDA approved in indication, NCCN guideline endorsed, clinical trial available).
  - Geolocation trial site feasibility: matching trials within 50 miles of the patient's primary residence with open recruitment slots.

#### 5. Trial Accrual Forecasting & Population Health Analytics
- Cohort feasibility modeling table for clinical trial sponsor biopharma partners:
  - Querying the 1.4M patient repository to estimate eligible patient pool sizes for 4 novel targeted therapy trial designs.
  - Quantifying screen failure risks (identifying overly restrictive exclusion criteria that eliminate 80%+ of candidate cohorts).
  - Projected recruitment velocity and trial completion timeline acceleration.

#### 6. Ethical Governance, Bias Mitigation & Data Privacy
- Algorithmic fairness and health equity governance: ensuring precision medicine trial matching algorithms do not under-represent historically underserved demographic cohorts.
- Patient consent management architecture: dynamic broad consent and granular trial re-contact permissions adhering to the Common Rule and 45 CFR 46.

---
### Presentation Standards:
- Present the deliverable as an executive, clinical-grade Precision Oncology & Health Informatics Dossier.
- Provide comprehensive Markdown tables for system architectures, eligibility criteria, patient matching demonstrations, and cohort feasibility.
- Bold all medical terms, gene names, mutation codes, NCT clinical trial identifiers, and regulatory standards.
- Provide complete, unclipped medical and technical specifications without placeholders.
